miglustat capsules — Medica

Initial criteria

• Diagnosis is established by ONE of the following (i or ii): i) Demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts; OR ii) Molecular genetic test showing biallelic pathogenic glucocerebrosidase (GBA) gene variants
• Medication is prescribed by or in consultation with a geneticist, endocrinologist, metabolic disorder subspecialist, or a physician who specializes in the treatment of Gaucher disease or related disorders

Approval duration

1 year